# Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems

## TL;DR

Brimonidine, originally used for glaucoma, is now a key treatment in dermatology for reducing facial redness and inflammation due to its vasoconstrictive and anti-inflammatory effects.

## Contribution

The paper highlights brimonidine's expanding dermatologic applications and advances in drug delivery systems to improve its efficacy and tolerability.

## Key findings

- Brimonidine effectively reduces facial erythema in rosacea and other skin conditions through vasoconstriction and anti-inflammatory action.
- New drug delivery systems like supramolecular hydrogels and lipid-based carriers enhance brimonidine's skin retention and therapeutic duration.
- Ongoing development of new quinoxaline–imidazoline analogues may lead to optimized α2-agonists for dermatologic use.

## Abstract

Brimonidine, a highly selective α2-adrenergic receptor agonist originally developed for glaucoma treatment, has emerged as an important dermatological agent due to its potent vasoconstrictive and anti-inflammatory properties. This review summarizes its pharmacological characteristics, and clinical applications. By activating α2-adrenergic receptors in cutaneous vessels, brimonidine induces rapid, reversible vasoconstriction and reduces neurogenic inflammation, leading to significant improvement of facial erythema in rosacea. Beyond its approved indication, topical brimonidine demonstrates efficacy in alcohol flushing syndrome, telangiectasia, post-procedural erythema, and as a local hemostatic agent in dermatologic surgery. Its favorable safety profile and minimal systemic absorption make it suitable for long-term use, though transient rebound erythema may occur. Advances in nanotechnology—such as supramolecular hydrogels and lipid-based carriers—enhance skin retention, prolong therapeutic action, and improve tolerability. These developments, together with ongoing synthesis of new quinoxaline–imidazoline analogues, open prospects for next-generation α2-agonists with optimized selectivity and dermatologic applicability. Brimonidine’s emerging role extends to dermatologic formulations for transient redness and sensitive skin management. Integrating pharmacological, formulation, and molecular insights may transform brimonidine from a niche rosacea therapy into a versatile platform for vascular, inflammatory, and aesthetic skin treatments.